Antiepileptic drugs used for the treatment of @entity410 have limited efficacy and undesirable side effects, leading to increased off-label use in neonates. Intravenous @entity4677 became available in August 2006 for use in @entity1 above 16 years of age. Insufficient data are available about the efficacy and safety of intravenous @entity4677 in neonates. Data captured from our institution's electronic medical records were retrospectively analyzed for neonates treated with intravenous @entity4677 between January 2007 and December 2009. Data were acquired by reviewing our electronic medical records. Twenty-two @entity1 received a @entity4677 load of 10-50 mg/kg for @entity410 . Nineteen of 22 @entity1 (86%) demonstrated immediate @entity410 cessation at 1 hour. Seven of 22 @entity1 (32%) achieved complete @entity410 cessation after administration of the loading dose, 14 (64%) achieved @entity410 cessation by 24 hours, 19 (86%) by 48 hours, and all 22 (100%) by 72 hours. No serious side effects were evident. Nineteen @entity1 (86%) were discharged on oral @entity4677 , and only two @entity1 (9%) were discharged with an additional oral antiepileptic drug. Intravenous @entity4677 can be used as monotherapy and adjunctively in acute @entity410 management during the neonatal period.

Use of intravenous @entity4677 for management of acute XXXX in neonates.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'neonatal seizures']
@entity410 :: (MESH:D012640,Disease) :: ['seizures']
